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Abstract
Pediatric neurological disorders represent a major part of the disabilities worldwide. In 
over 10 decades of research to find a cure for these disorders, medical science has not 
been able to repair the underlying brain injury. This chapter focuses on recent advances 
in the application of stem cells as a therapeutic tool for some of the common neurode‐
velopmental disorders (cerebral palsy, autism, intellectual disability and muscular dys‐
trophy). The mechanism of action of stem cells in each disorder has been explained. A 
review of clinical data has been described giving a clear understanding of current status 
of stem cell therapy in these disorders. Various factors influencing the outcome of stem 
cell therapy such as different types of cells, different routes of administration and dosage 
and frequency of transplantation have also been discussed. Our experience of treating 
these disorders is exhibited in the form of our published data. Use of novel monitoring 
tools such as MRI MSK and PET‐CT scan brain to track the changes occurring at cellular 
level after stem cell therapy are described. We also highlight the importance of a multi‐
disciplinary approach of combining rehabilitation with stem cell therapy.
Keywords: stem cell therapy, autism, cerebral palsy, muscular dystrophy, intellectual 
disability
1. Introduction
Neurodevelopmental disorders (NDD) are characterized by an abnormal development 
of the brain during the early development phase, leading to a myriad of symptoms and 
diseases, including delayed milestones and deficits in personal and social functioning [1]. 
The developmental deficits can vary from specific limitations of adaptive, behavioral and 
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cognitive functioning, motor dysfunction, to global impairments of social skills [2]. Some 
of the common neurodevelopmental disorders are cerebral palsy (CP), autism spectrum 
disorders, attention deficit hyperactivity disorder, intellectual disability (ID) or intellectual 
and developmental disability (IDD), learning disabilities, muscular dystrophies, Down’s 
syndrome, genetic disorders such as fragile‐X syndrome, spinal muscular atrophy (SMA) 
and metabolic disorders.
Pediatric neurological disorders represent a major part of the disabilities worldwide. In over 
10 decades of research to find a cure for these disorders, medical science has not been able 
to repair the underlying brain injury [3]. The causes of NDD can be classified as congeni‐
tal (present at birth) or acquired (developed after birth). The various etiologies are genetic 
defects, metabolic disorders, nutritional deficiencies, exposure to toxins, infections, hypoxia/
asphyxia, low birth weight, perinatal complications leading to traumatic brain injury or spi‐
nal cord injury in children [4]. This may affect language and speech, motor skills, behavior, 
memory, learning or other neurological functions affecting activities of daily life. While the 
severity of symptoms often change or evolve as the child’s age progresses, these disabilities 
remain permanent. As these are lifelong disabilities, they pose a substantial economic burden 
on the society [5]. Hence, finding a treatment for them is the need of the hour. Improvement 
in the performance of these children would be of great significance to the quality of life of 
patients and their families.
2. Unmet medical needs
Therapeutic strategies and clinical expectations of patients and medical professionals have not 
yet been met. Currently, available treatments such as physiotherapy, occupational therapy, 
behavioral therapy, psychological intervention, speech therapy and pharmacological inter‐
vention only focus on alleviating the symptoms of these disabilities and do not address the 
underlying neuropathophysiology. However, the advent of stem cell therapy has opened new 
avenues for treatment of pediatric neurological disorders. In recent years, extensive research 
has been done to explore the potential of stem cells for the treatment of pediatric neurological 
disabilities. Until now, it was believed that once injured, the cells of the central nervous sys‐
tem cannot regenerate. However, owing to the distinct properties of stem cells to repair and 
regenerate, they can be considered as a potential therapeutic strategy.
This chapter focuses on recent advances in the application of stem cells as a therapeutic tool 
for some of the common NDDs (cerebral palsy, autism, intellectual disability and muscu‐
lar dystrophy). The mechanism of action of stem cells in each disorder has been explained. 
A review of clinical data has been described giving a clear understanding of current status 
of stem cell therapy in these disorders. Various factors influencing the outcome of stem cell 
therapy such as different types of cells, different routes of administration and dosage and fre‐
quency of transplantation have also been discussed. Our experience of treating these disorders 
is exhibited in the form of our published data. Use of novel monitoring tools such as MRI MSK 
and PET‐CT scan brain to track the changes occurring at cellular level after stem cell therapy 
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is described. We also highlight the importance of a multidisciplinary approach of combining 
rehabilitation with stem cell therapy. Adverse effects of stem cell therapy are also enumerated.
3. What are stem cells?
Stem cells are blank, immature cells which have a capacity to self‐renew and differentiate into 
host‐specific multiple lineage cells [6]. Several types of stem cells are being explored for the 
treatment of neurological disorders such as bone marrow stem cells, embryonic stem cells, 
olfactory ensheathing cells and umbilical cord blood cells. The main aim of stem cell therapy 
is replacement of injured/dead neuronal cells and recovery of lost functions [7]. These cells 
perform repair process directly by regeneration of new cells or indirectly through paracrine 
activity. The chief underlying mechanisms of stem cells include neuroregeneration, neurore‐
placement, neuroprotection, immunomodulation, axon sprouting and neural circuit recon‐
struction [8] (Figure 1).
4. Mechanism of action of stem cells in pediatric neurological disorders
Pediatric neurological disorders are caused due to mechanisms affecting the molecular, cel‐
lular and tissue plasticity of the brain and nervous system [9].
Stem cells when transplanted migrate and home towards the injured areas of the brain [10]. 
This homing property is attributed to the expression of growth factors, chemokine and extra‐
cellular matrix receptors on the surface of cells such as stromal cell–derived factor 1 (SDF‐1), 
monocyte chemo attractant protein‐3 (MCP‐3), stem cell factor (SCF) and/or IL‐8. They dif‐
ferentiate into the host tissue cells and replace the injured/dead neuronal tissue [11]. Through 
paracrine mechanisms they halt further injury and stimulate endogenous cells to carry out the 
repair and restoration process [12]. Stem cells secrete a vast array of neuroprotective growth 
factors including brain‐derived neurotrophic factor (BDNF), nerve growth factor (NGF), 
neurotrophin‐3 (NT‐3), glial cell line–derived neurotrophic factor (GDNF) and insulin‐like 
Figure 1. Mechanism of action of stem cells in pediatric neurological disorders.
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growth factor type 1. These growth factors activate a number of signaling pathways and 
help in enhancing differentiation, survival of neurons and maintaining neuronal functions 
[13]. They also produce vascular endothelial growth factor (VEGF), hepatocyte growth fac‐
tor (HGF) and basic fibroblast growth factor (FGF‐2) which improve perfusion and enhance 
angiogenesis [14]. Anti‐inflammatory paracrine factors such as Interleukin 10 (IL 10) and 
Transforming growth factor (TGF)‐β help in immunomodulation [15].
5. Clinical application of stem cell therapy in NDD
In this section, we discuss the literature review of various stem cell therapy studies in each 
disorder followed by our experience.
We published a study of 71 children diagnosed with different incurable neurological disor‐
ders. Autologous bone marrow–derived mononuclear cells were transplanted intrathecally 
and intramuscularly. Improvements were noted in muscle power, functional independent 
measure (FIM) and Brooke and Vignos scale. Imaging and electrophysiological investigations 
also showed improvement. Overall 97% muscular dystrophy cases showed subjective, func‐
tional and investigational improvement. Eighty‐five percent of cases of cerebral palsy cases 
showed improvements. Eighty‐eight percent of cases of other incurable neurological disor‐
ders such as autism, Retts syndrome and giant axonal neuropathy also showed improvement. 
No major adverse events were noted.
6. Stem cell therapy in cerebral palsy
In cerebral palsy, white matter injury also known as periventricular leukomalacia (PVL) is one of 
the major pathologies observed [16]. Stem cells differentiate into neurons, oligodendrocytes and 
astrocytes which replace and repair the white matter injury in CP [17] (Figure 2). The growth 
factors secreted by these cells also help in remyelination, synaptogenesis, cytoprotection and 
angiogenesis which reverse the cellular injury in CP [18, 19]. Numerous preclinical studies have 
Figure 2. Stem cell therapy in cerebral palsy.
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demonstrated the potential of stem cell transplantation in cerebral palsy. The homing property 
of these cells was confirmed by Chen et al., who transplanted magnetically labeled mesenchy‐
mal stem cells in a model of perinatal brain injury and found that these cells migrate to lesion 
sites and proliferate [20]. Studies have demonstrated the differentiation of bone marrow, umbil‐
ical cord blood, neural and other progenitor stem cells into neurons and oligodendrocytes in 
experimental animal models [21–25]. Transplantation of stem cells in rat models have resulted 
in improved cognition and sensorimotor deficits along with functional recovery [26].
6.1. Clinical evidence
In cerebral palsy, around 26 studies have been published explaining the effect of stem cell ther‐
apy. Overall, 579 (90%) out of 646 patients have shown improvements (Table 1) [20, 27–51].
Sr. no Citations Cells used Route of 
administration
Sample 
size
Patient 
improved
Adverse events
1. Sharma et al. [27] Autologous bone marrow 
mononuclear cells 
(BMMNCs)
Intrathecal 40 None
2. Min et al. [28] Allogenic umbilical cord 
blood
Intravenous 96 86 Pneumonia and 
irritability
3. Lee et al. [29] Autologous umbilical cord 
blood
Intravenous 20 5 Nausea, 
hemoglobinuria or 
urticaria
4. Purandare et al. 
[30]
Autologous BMMNCs Intrathecal 1 1 None
5. Chen et al. [20] Autologous bone marrow 
mesenchymal cells
Subarachnoid 60 60 Increased 
frequency of 
crying
6. Li et al. [31] Autologous bone marrow 
mesenchymal cells
Subarachnoid 1 1 None
7. Luan et al. [32] Neural progenitor cells Intracranial 45 45 None
8. Chen et al. [33] Olfactory ensheathing cells Intracranial 33 33 None
9. Ramirez et al. [34] Umbilical cord blood cells Intramuscular 
injection
8 8 Localized mild 
pain at the site of 
injection.
10. Payne [35] Umbilical cord blood cells Subcutaneous 16 16 None
11. Sharma et al. [36] Autologous BMMNCs Intrathecal 1 1 None
12. Sharma et al. [37] Autologous BMMNCs Intrathecal 1 1 None
13. Papadopoulos et 
al. [38]
Autologous BMMNCs Intrathecal 2 2 None
14. Sharma et al. [39] Autologous BMMNCs Intrathecal 1 1 None
15. Jensen and 
Hamelmann [40]
Autologous umbilical cord 
blood cells
Intravenous 1 1 None
16. Wang et al. [41] Umbilical cord 
mesenchymal stem cells
Intravenous 
and intrathecal 
administration
1 1 Temporary low‐
grade fever
17. Luan et al. [42] Human neural stem cells Intracerebral 7 4 None
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In 2015, we published a nonrandomized study demonstrating the benefits of autologous bone 
marrow mononuclear cells (BMMNCs) in cerebral palsy [27]. These patients were followed 
up at 3 and 6 months. Six months after intervention, 38 out of 40 (95%) patients showed 
improvements and 2 did not show any improvement but remained stable without any dete‐
rioration (Figure 3). No major adverse events were noted except for seizures in two patients 
which were controlled by medications.
Sr. no Citations Cells used Route of 
administration
Sample 
size
Patient 
improved
Adverse events
18. Wang et al. [43] Bone marrow 
mesenchymal stromal cells
– 52 52 none
19. Yang et al. [44] Umbilical cord 
mesenchymal stem cell
Intravenous 
and intrathecal
25 22 none
20. Zali et al. [45] CD133‐positive enriched 
bone marrow progenitor 
cells
Intrathecal 12 12 seizure
21. Mancías‐Guerra 
et al. [46]
Autologous bone marrow–
derived total nucleated cell 
(TNC)
Intrathecal and 
intravenous 
injection
18 18 Headache, 
vomiting, fever 
and stiff neck
22. Romanov et al. 
[47]
Allogenic umbilical cord 
blood cells
Intravenous 80 80 None
23. Zang et al. [48] Umbilical cord blood 
mesenchymal stem cells
Intravenous 1 1 None
24. Wang et al. [49] Umbilical cord–derived 
mesenchymal stromal cell
Subarachnoid 16 (8 
pair of 
twins)
16 (8 pair 
of twins)
None
25. Shroff et al. [50] Human embryonic stem 
cells
Intravenous 91 63 Seizures
26. Abi Chahine et 
al. [51]
Bone marrow 
mononuclear cells
Intrathecal 17 11 Headaches, 
transient fever and 
vomiting
Table 1. Clinical evidence demonstrating the use of stem cells in cerebral palsy.
Figure 3. Graph showing improvement in children with cerebral palsy after stem cell therapy.
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We have also published three case reports demonstrating the safety and efficacy of BMMNC 
transplantation in cerebral palsy [36, 37, 39]. In these case reports, the functional improve‐
ments are supported by improved brain metabolism recorded in comparative PET‐CT scans 
performed before and after the intervention.
7. Stem cell therapy in autism
In autism, immune dysfunction, hypoperfusion, oxidative stress, decreased number of 
Purkinje cells (PCs), cerebellum alterations, defective cortical organization and altered plas‐
ticity of dendritic spine morphology are the underlying neuropathologies (Figure 4) [52, 53]. 
Stem cells modulate the immune dysfunction by releasing anti‐inflammatory molecules and 
inhibiting pro‐inflammatory molecules, which further reduces neural injury [54]. They also 
facilitate angiogenesis which increases blood and oxygen supply to the brain thus reversing 
the hypoperfusion [55]. Stem cells may also reinforce cortical plasticity, promote synaptic 
plasticity and restore cerebellar PCs [56]. These mechanisms collectively may improve the 
lost neural connectivity and restore lost functions in autism. In an experimental model of 
mice, H Segal Gavish et al. transplanted mesenchymal stem cells, which resulted in reduction 
of stereotypical behaviors, decrease in cognitive rigidity and improvement in social behav‐
ior. Tissue analysis revealed elevated BDNF protein levels in the hippocampus accompanied 
by increased hippocampal neurogenesis in the MSC‐transplanted mice compared with sham 
treated mice [57].
7.1. Clinical evidence
A total of 11 studies (3 case series and 8 case reports) have been published all over the world 
demonstrating the benefits of stem cell therapy in autism. Overall, 122 patients were adminis‐
tered with cellular therapy and 90 showed improvements (Table 2) [58–68].
Figure 4. Stem cell therapy in autism.
Stem Cell Therapy in Pediatric Neurological Disabilities
http://dx.doi.org/10.5772/67656
123
In 2013, we published an open label proof of concept study which included 32 patients of autism 
[58] (Figure 5). These patients were followed up for 26 months (mean 12.7). The outcome mea‐
sures used were Childhood Autism Rating Scale (CARS), Indian Scale for Autism Assessment 
(ISAA), Clinical Global Impression (CGI) and Functional Independence Measure (FIM/Wee‐FIM) 
scales. It was found that out of 32 patients, a total of 29 (91%) patients improved on total ISAA 
Author Type of cells used Route of 
administration
Sample size How many 
patients 
improved
Demonstrated safety
Sharma et al. [58] Autologous bone 
marrow mononuclear 
cells (BMMNCs)
Intrathecal 32 29 Yes
Lv et al. [59] Human cord blood 
mononuclear cells 
(CBMNCs) and 
umbilical cord–derived 
mesenchymal stem 
cells (UCMSCs)
Intravenous and 
intrathecal
37 18 Yes
Bradstreet et al. 
[60]
Fetal stem cells Subcutaneous 45 35 Yes
Sharma et al. [61] Autologous BMMNCs Intrathecal 1 1 Yes
Sharma et al. [62] Autologous BMMNCs Intrathecal 1 1 Yes
Sharma et al. [63] Autologous BMMNCs Intrathecal 1 1 Yes
Sharma et al. [64] Autologous BMMNCs Intrathecal 1 1 Yes
Sharma et al. [65] Autologous BMMNCs Intrathecal 1 1 Yes
Sharma et al. [66] Autologous BMMNCs Intrathecal 1 1 Yes
Sharma et al. [67] Autologous BMMNCs Intrathecal 1 1 Yes
Sharma et al. [68] Autologous BMMNCs Intrathecal 1 1 Yes
Table 2. Clinical evidence demonstrating the use of stem cells in autism.
Figure 5. Graph showing percentage improvement in various symptoms of autism post stem cell therapy.
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scores and 20 patients (62%) showed decreased severity on CGI‐I. On CGI‐II 96% of patients 
showed global improvement. Improvements in brain metabolism were also observed on posi‐
tron emission tomography‐computed tomography (PET‐CT) scan brain. All 32 patients were 
monitored through the duration of follow‐up for any major adverse events. Incidence of seizures 
was recorded in three patients, which were reversible and easily controlled with medications.
In addition to the above study, we have also published eight case reports demonstrating the 
safety, efficacy and objective improvements on PET‐CT scan brain in patients with autism 
following stem cell therapy [61–68].
8. Stem cell therapy in intellectual disability
In intellectual disability (ID), the neuronal connectivity in the brain is impaired along with 
disrupted cell migration, cell multiplication, axon growth, brain plasticity and synaptogen‐
esis (Figure 6) [9]. Studies have recorded defects in hippocampus and cerebral cortex areas 
of the brain leading to faulty information processing, consecutively affecting cognition and 
adaptive behavior in ID. Stem cells restore the synaptic transmitters released and provide 
local reinnervations to the area affected. It also integrates existing neural and synaptic net‐
work and re‐establishes connections of functional afferent and efferent cells which may have 
contributed in restoring the cognitive and functional deficit in IDs [69].
8.1. Clinical evidence
We are currently under process of analyzing the data of a prospective study conducted to 
demonstrate the effect of autologous bone marrow mononuclear cells in intellectual disability. 
Figure 6. Stem cell therapy in intellectual disabilities.
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However, in 2015, we published a report of a 13‐year‐old boy with intellectual disability who 
exhibited improvements after stem cell therapy [70]. He was followed up after 3 and 6 months 
of intervention. No major adverse events were recorded post intervention. Over a period of 
6 months, he showed improved eye contact, cognition, learning ability, behavior and ability 
to perform activities of daily living. His score on Functional Independence Measure (FIM) 
increased from 67 to 76. On comparing the pre and post PET‐CT scan, improvement in meta‐
bolic activity of hippocampus, left amygdala and cerebellum was recorded. These changes 
correlated to the functional outcome.
9. Stem cell therapy in Duchenne muscular dystrophy
The underlying pathogenic mechanism of muscular dystrophy is an imbalance between 
muscle degeneration and resident satellite cell–mediated regeneration [71]. Satellite cells, 
the adult skeletal muscle progenitor cells, are considered to be the main cell type involved in 
skeletal muscle regeneration. Continuous cycles of degeneration and regeneration of muscle 
fibers exhausts the muscle stem cell pool, leading to muscle being replaced by adipose and 
fibrotic tissue. Stem cell therapy holds great promise as a treatment for Duchenne muscular 
dystrophy by providing cells that can both deliver functional muscle proteins and replenish 
the stem cell pool [72].
Stem cells are known to enhance angiogenesis, contribute to neovascularization, promote 
tissue remodeling, prevent apoptosis, decrease inflammation, release growth factors and 
activate the satellite cells [73] (Figure 7). In animal models, these cells have shown to  produce 
the deficient proteins and make new muscle cells which fuse with the host fibers. Further, 
stem cell–derived exosomes which are small membrane vesicles and are responsible for 
inter‐cellular communication, promote muscle regeneration by enhancing myogenesis and 
angiogenesis [74].
Figure 7. Role of stem cells in muscular dystrophy.
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9.1. Clinical evidence
A total of 14 studies have been conducted demonstrating the efficacy of stem cells in muscu‐
lar dystrophy. Various types of stem cells such as bone marrow–derived cells, umbilical cord 
stem cells and muscle‐derived cells were used. Out of a total of 346 patients who underwent 
stem cell therapy, 296 showed a positive outcome (Table 3) [75–90].
Author Sample 
size
Type of cells used Route of 
administration
Number of patients improved Level of 
evidence
Torrente et al. [75] 8 Muscle‐derived CD133+ 
cell
Intramuscular 8 4
Yang et al. [76] 82 Autologous bone 
marrow mesenchymal 
stem cells (BMSC) 
and umbilical cord 
mesenchymal stem cells 
(UMSC)
Intravenous 
and 
intramuscular
Effective in 68 [82.9%] cases. 4
Mendell et al. [77] 12 Muscle precursor cells Intramuscular In one patient, 10.3% of muscle 
fibers expressed donor‐
derived dystrophin after 
myoblast transfer. Three other 
patients also had a low level 
of donor dystrophin; eight 
had none.
4
Sharma et al [78] 150 BMMNCs Intrathecal, 
Intramuscular
130 [86.67%] cases showed 
symptomatic and functional 
improvements
4
Rajput et al. [79] 16 Human umbilical cord 
mesenchymal stem cells
IV and IM 
injection
9 out of 11 patients were stable 
no deterioration.
Sharma et al. [80] 65 BMMNCs Intrathecal, 
Intramuscular
65 (plateau phase, no further 
progression)
4
Skuk et al. [81] 1 Muscle‐precursor cells Intramuscular 27.5% of the myofiber profiles 
expressed donor‐derived 
dystrophin, 1 month post‐
transplantation and 34.5%, 18 
months post‐transplantation
5
Sharma et al. 
[82–87]
6 case 
reports
BMMNCs Intrathecal, 
Intramuscular
6 5
Kang et al. [88] 1 Umbilical cord–derived 
hematopoietic stem cell
Intrathecal not effective 5
Skuk et al. [89] 3 Myogenic cells Intramuscular dystrophin‐positive myofibers 
in the cell‐grafted sites 
amounting to 9 (patient 1), 6.8 
(patient 2) and 11% (patient 3).
Zhang et al. [90] 1 Allogeneic cord blood 
stem cells
Intravenous 1 5
Table 3. Clinical evidence demonstrating the use of stem cells in muscular dystrophy.
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We conducted a study on 150 patients diagnosed with muscular dystrophy. On a mean fol‐
low up period of 12 months ± 1 month, 86.67% cases showed symptomatic and functional 
improvements, with six patients showing muscle regeneration and decrease in fatty infil‐
tration on musculoskeletal magnetic resonance imaging (MRI MSK) and nine showing 
improved muscle electrical activity on electromyography (EMG). Fifty‐three percent cases 
showed increase in trunk muscle strength, 48% an increase in upper limb (UL) strength, 59% 
an increase in lower limb (LL) strength and about 10% showed an improved gait pattern 
(Figures 8 and 9).
Figure 8. Graph showing improvements in muscular dystrophy patients after stem cell therapy. y‐axis = number of 
patients (n = 150).
Figure 9. Graph showing symptomatic improvements in muscular dystrophy patients after stem cell therapy. Number 
of patients showing improvements in trunk strength, upper limb (UL) strength, lower limb (LL) strength, gait pattern, 
and standing function are shown. y‐axis = number of patients (n = 150).
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10. Adverse events of stem cell therapy
The adverse events following stem cell transplantation mainly depends on the type of stem 
cell and the route of administration. Other factors like dosage of cells, frequency of trans‐
plantation and age of the patient may also contribute. Fetal stem cells are known to be poten‐
tially tumorigenic [91]. Use of umbilical cord stem cells is limited due to slow or incomplete 
immune reconstitution, resulting in a high transplantation‐related mortality (TRM) due to 
infections. Most studies have demonstrated a predominance of Gram‐positive bacteria (GPB) 
bloodstream infections [92]. On the contrary, adult stem cell has not shown any serious 
adverse events. Autologous cell transplantation is safer than allogenic.
Adverse events of stem cell therapy can be categorized into minor and major adverse events. 
Minor adverse events include procedure related events such as spinal headache, nausea, diar‐
rhea, vomiting, pain or bleeding at the site of aspiration/injection and fever amongst others. 
These are treated using medications. Anesthetic complications and allergic reactions may 
also occur depending on the procedure. Major adverse events include episodes of seizures 
occurring after intervention. These can be managed prophylactically. Pre‐existing epilepto‐
genic focus in Electroencephalogram (EEG) also predicts the occurrence of seizures. Evidence 
 suggests that antiepileptic prophylactic regimen decreases the incidence of seizures as an 
adverse event after stem cell therapy [93].
11. Factors influencing the outcome of stem cell therapy for NDDs
11.1. Routes of administration
The route of delivery of cells plays an important role in maximizing the clinical output of 
cellular therapy. Intrathecal route of administration is a relatively minimally invasive and tar‐
geted route of administration of cells. It is devoid of any major side effects [94]. In neurologi‐
cal disorders, intrathecal transplantation enhances the accessibility of the injected cells into 
the CNS [95]. Intramuscular injections are administered at the motor points plotted on the 
affected muscles. Motor points are the points where the innervating nerve enters the muscle. 
Thus, implantation of cells in the muscles enhances the effect of stem cells on the degenerating 
muscles [96]. Intravenous administration is the least invasive route. However, evidence sug‐
gests that majority of cells get trapped in the pulmonary passage and only few cells reach the 
injured site [97]. An alternate route of administration is via intra‐cerebral route. But, it is an 
invasive technique and might result in secondary complications such as bleeding and neural 
tissue injury [98]. Hence, as compared to all the delivery routes, intrathecal administration is 
most efficacious.
11.2. Types of cells
Cells used from allogenic sources have an inherent risk of immunogenicity and may poten‐
tially cause immune rejection of graft versus host disease. Autologous cells have the least 
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 possibility of immune reaction and so far clinical studies with autologous minimally manipu‐
lated cells have shown no immunogenic reactions in the host post transplantation. Autologous 
cells may therefore be a safer option in children with NDD.
11.3. Etiology
Genetic factors play a major part in the pathology of neurological disorders and gene 
therapy has provided novel insights in treating the underlying genetic aberrations. But 
gene therapy cannot replace the lost neurons and practical difficulties have prevented it 
from being a clinically feasible and viable option at present. The sporadic nature of the 
disease is also an important factor influencing the outcome, where the etiology of the dis‐
ease is unknown. Stem cell therapy addresses the core injury occurring in the brain. The 
multiple mechanism of action of the stem cells addresses the multifactorial pathology of 
the NDD.
11.4. Severity
It has been observed that the mild cases of neurodevelopment disorders have a better recov‐
ery curve than the chronic cases. In mild cases, axonal function remains intact and recovery 
can be rapid if remyelination occurs. In severe cases, axonal degeneration occurs and recov‐
ery depends on axonal regeneration. Recovery becomes much slower, and there is a greater 
degree of residual injury. Mild cases require lesser dosage of cells and the frequency of doses 
required is less to attain potential recovery than the severe cases.
11.5. Age of the patient
One of postulated hypothesis is that the neural circuits, that form the basis for learning, 
behavior and health, are more plastic during the initial years of life. They become increasingly 
difficult to alter over time. Age‐related decline in the potency of the stem cells is observed 
which might also affect the remodeling of CNS by these cells. Early intervention is advised for 
better outcome of stem cell therapy.
12. Importance of neurorehabilitation
Neurorehabilitation aims at restoration and maximization of functions that have been lost due 
to impairments caused by injury or disease of nervous system making the patient functionally 
independent. The rehabilitation regime promotes and facilitates neural plasticity [99]. Studies 
have shown that exercise enhances the effect of injected stem cells by inducing mobility of 
the cells, activating and proliferating the local stem cells, promoting muscle angiogenesis and 
release of cytokines and nerve growth factors. Hence, neurorehabilitation compliments with 
the stem cell therapy [100].
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13. Objective evidence: neuroimaging techniques to monitor the outcome 
of stem cell therapy
Neuroimaging techniques enable the quantitative measurement of various biological mark‐
ers which may serve as a powerful tool for optimizing the use of stem cells for clinical 
applications.
13.1. Positron emission tomography (PET‐CT) scan brain
PET‐CT scan brain can be used efficiently as a monitoring tool to study the outcome of stem 
cell therapy. One of the advantages of using PET‐CT is its extreme sensitivity enabling it 
to detect molecules at the nanomolar level [101]. Brain 18F‐FDG PET allows studying the 
cerebral glucose metabolism, indicating the neuronal and synaptic activity. It dynamically 
measures the energy metabolism along with blood oxygenation and blood flow [102]. The 
alteration in neuronal activity caused by disease is reflected in change of glucose metabolism 
and can be revealed in the PET‐CT scan brain. As mentioned previously in the clinical results, 
there were improvements recorded in the brain metabolism of patients included in the clini‐
cal studies. The changes seen on PET‐CT scan brain correlated with the clinical improvement 
indicating that it can identify alteration occurring at the tissue levels (Figures 10–12).
13.2. Magnetic resonance imaging (MRI)
Magnetic resonance imaging (MRI) is gaining popularity because of its capacity to reveal 
characteristic findings that address the diagnosis and support therapeutic interventions. 
Figure 10. (A) Pre SCT PET‐CT scan images with blue areas indicating hypometabolism. (B) These areas have almost 
disappeared after SCT as seen in the post PET‐CT scan image. This shows improvement in the metabolism/functioning 
in the affected areas of the brain after SCT.
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Since MRI is devoid of ionizing radiations, it has turned out to be a valuable imaging method 
in children, although sometimes sedation might be necessary. In the past few years, studies 
have reported on the detection of muscle involvement pattern in various muscular dystro‐
phies through MRI musculoskeletal imaging (MRI/MSK). The images provide a high soft 
tissue contrast allowing assessment of affected striated muscles in terms of shape, volume 
(hypotrophy and hypertrophy) and architecture [103, 104]. MRI MSK was used as a tool to 
Figure 11. Findings in PET‐CT scan before and after cellular therapy. (a) PET‐CT scan before intervention showing 
reduced FDG uptake in the areas of frontal lobe, cerebellum, amygdala, hippocampus, parahippocampus, and mesial 
temporal lobe. (b) PET‐CT scan six months after intervention comparison shows increased FDG uptake in the areas of 
frontal lobe, cerebellum, amygdala, hippocampus, parahippocampus, and mesial temporal lobe.
Figure 12. (A) Pre stem cell therapy PET‐CT scan showing blue areas with hypometabolism. (B) Post stem cell 
therapy PET‐CT scan showing decrease in blue areas which is replaced by green areas indicating improved 
functioning of the brain.
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assess the therapeutic efficacy of stem cell therapy in muscular dystrophy. In our published 
data, images of MRI MSK performed after intervention has revealed stabilization of disease 
progression in muscular dystrophy.
14. Conclusion
In children, the brain is still at a developing stage and not fully matured resulting in 
maximal neural plasticity during childhood. Hence, likelihood of improvement in affected 
areas of the brain increases manifold with early intervention. Stem cell therapy has recently 
gained lot of importance as a therapeutic strategy for various disorders including NDDs. 
In this review, we have demonstrated the outcome of stem cell therapy in NDDs mainly 
cerebral palsy, autism, intellectual disability and muscular dystrophy supported by our 
published data. Through its neurorestorative and neuroregenerative property, stem cells 
have the capacity of repairing the underlying neural and muscular dysfunction. This prop‐
erty can augment neurodevelopment, facilitating achievement of milestones earlier as 
compared to the current conventional treatment modalities. In progressive developmen‐
tal disorders like muscular dystrophies, stem cell therapy has shown to slow down the 
disease progression. The data also establishes the fact that autologous stem cell therapy 
is a safe and efficacious treatment which helps in recovery of lost functions and neural 
plasticity.
Though stem cell therapy is not a cure, the gap between normalcy and disability can be 
minimized. Stem cells in combination with the multidisciplinary medical and rehabilitative 
modalities can enhance and hasten the recovery from NDD which will help the patient to lead 
a productive and respectable life in the society.
15. Future directions
Stem cell therapy is still in its developing stage. There are still numerous uncertainties pre‐
vailing with respect to optimum volume of cells to be injected, number of doses, route of 
administration, types of cells amongst others. The advent of induced pluripotent stem cells 
(iPSCs) has provided opportunities for the study of human neurodevelopmental diseases 
in a controlled environment. Reprogramming cells from patients with neurological dis‐
eases will allow the study of disease‐specific cellular and molecular pathways causing these 
diseases. Also, the establishment of neural stem cells (NSCs), a life‐long source of neurons 
and glia, has contradicted the dogma that the nervous system lacked regenerative power. 
Future studies need to focus on the precautionary pre‐intervention assessments to identify 
patients with high risk for seizures and related adverse events after stem cell therapy. A 
better knowledge of all these factors will improve the therapeutic effectiveness of stem cell 
therapy. Future studies should consider the use of modern radiological tools as monitoring 
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tool and substantiate the effects of cellular therapy in NDDs. Large scale, multicentre and 
randomized controlled trials are recommended to further establish the safety and efficacy 
of cellular therapy.
Author details
Alok Sharma1, Hemangi Sane2, Nandini Gokulchandran1, Prerna Badhe3, Pooja Kulkarni2,3, 
Suhasini Pai2, Ritu Varghese2 and Amruta Paranjape2,4
*Address all correspondence to: poojakul28@gmail.com
1 Department of Medical Services and Clinical research, NeuroGen Brain & Spine Institute, 
Navi Mumbai, India
2 Department of Research & Development, NeuroGen Brain & Spine Institute, Navi Mumbai, 
India
3 Department of Regenerative Laboratory Services, NeuroGen Brain & Spine Institute, Navi 
Mumbai, India
4 Department of Neurorehabilitation, NeuroGen Brain & Spine Institute, Navi Mumbai, India
References
[1] Telias M, Ben‐Yosef D. Modeling neurodevelopmental disorders using human pluripo‐
tent stem cells. Stem Cell Reviews and Reports. 2014;10(4):494–511
[2] American Psychiatric Association. Neurodevelopmental Disorders: DSM‐5® Selections. 
Arlington, VA: American Psychiatric Pub; 2015
[3] Mullin AP, Gokhale A, Moreno‐De‐Luca A, Sanyal S, Waddington JL, Faundez, V. 
Neurodevelopmental disorders: Mechanisms and boundary definitions from genomes, 
interactomes and proteomes. Translational Psychiatry. 2013;3(12):e329
[4] Kelleher E, Corvin A. Overlapping etiology of neurodevelopmental disorders. In: 
Mitchell KJ, editor. The Genetics of Neurodevelopmental Disorders. New Jersey: John 
Wiley & Sons, Inc. 2015.
[5] World Health Organization. Neurological Disorders: Public Health Challenges. Geneva: 
World Health Organization; 2006.
[6] Ul Hassan A, Hassan G, Rasool Z. Role of stem cells in treatment of neurological disor‐
der. International Journal of Health Sciences. 2009;3(2):227–233
[7] Lindvall O, Björklund A. Cell replacement therapy: Helping the brain to repair itself. 
NeuroRx. 2004;1(4):379–381
Physical Disabilities - Therapeutic Implications134
[8] Karussis D, Kassis I, Kurkalli BG, Slavin S. Immunomodulation and neuroprotection 
with mesenchymal bone marrow stem cells (MSCs): A proposed treatment for mul‐
tiple sclerosis and other neuroimmunological/neurodegenerative diseases. Journal of 
Neurological Science. 2008;265(1‐2):131–135
[9] Kroon T, Sierksma MC, Meredith RM. Investigating mechanisms underlying neurode‐
velopmental phenotypes of autistic and intellectual disability disorders: A perspective. 
Frontiers in Systems Neuroscience. 2013;7:75
[10] Smart N, Riley PR. The stem cell movement. Circulation Research. 2008;102(10):1155–1168
[11] Verma RS. Breaking dogma for future therapy using stem cell – Where we have reached? 
The Indian Journal of Medical Research. 2016;143(2):129–131
[12] Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. 
Regenerative Medicine. 2010;5(1):121–143
[13] Hung C‐W, Liou Y‐J, Lu S‐W, et al. Stem cell‐based neuroprotective and neurorestor‐
ative strategies. International Journal of Molecular Sciences. 2010;11(5):2039–2055
[14] Crisostomo PR, Wang M, Herring CM, Markel TA, Meldrum KK, Lillemoe KD, et al. 
Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, 
IL‐6 expression: role of the 55 kDa TNF receptor (TNFR1). Journal of Molecular and 
Cellular Cardioliology. 2007;42(1):142–149
[15] Markel TA, Crisostomo PR, Wang M, Herring CM, Meldrum DR. Activation of indi‐
vidual tumor necrosis factor receptors differentially affects stem cell growth factor and 
cytokine production. American Journal Physiology Gastrointestinal Liver Physiology. 
2007;293(4):G657–G662
[16] Khwaja O, Volpe JJ. Pathogenesis of cerebral white matter injury of prematurity. Archives 
of Disease in Childhood Fetal and Neonatal Edition. 2008;93(2):F153‐F161
[17] Castillo‐Melendez M, Yawno T, Jenkin G, Miller SL. Stem cell therapy to protect and 
repair the developing brain: A review of mechanisms of action of cord blood and amnion 
epithelial derived cells. Frontiers in Neuroscience. 2013;7:194.
[18] Giulian D, Johnson B, Krebs JF, Tapscott MJ, Honda S. A growth factor from neuronal cell 
lines stimulates myelin protein synthesis in mammalian brain. Journal of Neuroscience. 
1991;11(2):327–336
[19] Garofalo L, Ribeiro‐da‐Silva A, Cuello AC. Nerve growth factor‐induced synaptogenesis 
and hypertrophy of cortical cholinergic terminals. Proceeding of National Academy of 
Sciences of the United States of America. 1992;89:2639–2643
[20] Chen G, Wang Y, Xu Z, Fang F, Xu R, Wang Y, Hu X, Fan L, Liu H. Neural stem cell‐like 
cells derived from autologous bone mesenchymal stem cells for the treatment of patients 
with cerebral palsy. Journal of Translational Medicine. 2013;11:21
Stem Cell Therapy in Pediatric Neurological Disabilities
http://dx.doi.org/10.5772/67656
135
[21] Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone mar‐
row stromal cells differentiate into neurons.Journal of Neuroscience Research. 
2000;61:364–370
[22] Wang XL, Zhao YS, Hu MY, Sun YQ, Chen YX, Bi XH. Umbilical cord blood cells regu‐
late endogenous neural stem cell proliferation via hedgehog signaling in hypoxic isch‐
emic neonatal rats. Brain Research. 2013;1518:26–35
[23] Park KI, Himes BT, Stieg PE, Tessler A, Fischer I, Snyder EY. Neural stem cells may 
be uniquely suited for combined gene therapy and cell replacement: evidence from 
engraftment of Neurotrophin‐3‐expressing stem cells in hypoxic‐ischemic brain injury. 
Experimental Neurology. 2006;199(1):179–190.
[24] Yasuhara T, Matsukawa N, Yu G, Xu L, Mays RW, Kovach J, Deans RJ, Hess DC, Carroll 
JE, Borlongan CV. Behavioral and histological characterization of intrahippocampal 
grafts of human bone marrow‐derived multipotent progenitor cells in neonatal rats with 
hypoxic‐ischemic injury. Cell Transplant. 2006;15(3):231–238.
[25] Webber DJ, van Blitterswijk M, Chandran S. Neuroprotective effect of oligodendrocyte 
precursor cell transplantation in a long‐term model of periventricular leukomalacia. 
American Journal of Pathology. 2009;175(6):2332–2342
[26] Pimentel‐Coelho PM, Magalhães ES, Lopes LM, deAzevedo LC, Santiago MF, Mendez‐
Otero R. Human cord blood transplantation in a neonatal rat model of hypoxic‐ischemic 
brain damage: Functional outcome related to neuroprotection in the striatum. Stem Cells 
and Development. 2010;19(3):351–358
[27] Sharma A, Sane H, Gokulchandran N, Kulkarni P, Gandhi S, et al. A clinical study of 
autologous bone marrow mononuclear cells for cerebral palsy patients: a new frontier. 
Stem Cells International. 2015;2015:11 pages. Article ID 905874
[28] Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS, Jang SJ, Kim SH, Oh D, Kim MK, Kim 
SS, Kim M. Umbilical cord blood therapy potentiated with erythropoietin for children 
with cerebral palsy: A double‐blind, randomized, placebo‐controlled trial. Stem Cells. 
2013;31(3):581–591
[29] Lee YH, et al. Safety and feasibility of countering neurological impairment by intrave‐
nous administration of autologous cord blood in cerebral palsy. Journal of Translational 
Medicine. 2012;10:58
[30] Purandare C, Shitole DG, Belle V, Kedari A, Bora N, Joshi M. Therapeutic potential of 
autologous stem cell transplantation for cerebral palsy. Case Reports in Transplantation. 
2012;2012:825289
[31] Li M, Yu A, Zhang F, Dai GH, Cheng H, Wang X, An Y. Treatment of one case of cerebral 
palsy combined with posterior visual pathway injury using autologous bone marrow 
mesenchymal stem cells. Journal of Translational Medicine. 2012;10:100
Physical Disabilities - Therapeutic Implications136
[32] Luan Z, Liu W, Qu S, Du K, He S, Wang Z, Yang Y, Wang C, Gong X. Effects of neural pro‐
genitor cell transplantation in children with severe cerebral palsy. Cell Transplantation. 
2012;21(Suppl 1):S91‐S98
[33] Chen L, Huang H, Xi H, Xie Z, Liu R. Intracranial transplant of olfactory ensheathing 
cells in children and adolescents with cerebral palsy: A randomized controlled clinical 
trial. Cell Transplantation. 2010;19(2):185–191.
[34] Ramirez F, Steenblock D, Payne AG, Darnall L. Umbilical cord stem cell therapy for 
cerebral palsy. Medical Hypotheses and Research. 2006;3:679–686
[35] Payne G. Beneficial effects of subcutaneously injected human umbilical cord stem cells 
on cerebral palsy and traumatic brain injury in children and a posited mechanism. 
Medical Hypotheses and Research. 2005;2(3):497–501
[36] Sharma A, Sane H, Paranjape A, Gokulchandran N, Kulkarni P, Nagrajan A, Badhe P. 
Positron emission tomography–computer tomography scan used as a monitoring tool 
following cellular therapy in cerebral palsy and mental retardation – A case report. Case 
Reports in Neurological Medicine. 2013;2013:6 pages. Article ID 141983
[37] Sharma A, Kulkarni P, Sane H, Gokulchandran N, Badhe P, Lohia M, Mishra P. Positron 
emission tomography–computed tomography scan captures the effects of cellular ther‐
apy in a case of cerebral palsy. Journal of Clinical Case Reports. 2012;2:195
[38] Papadopoulos KI, Low SS, Aw TC, Chantarojanasiri T. Safety and feasibility of autolo‐
gous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of 
low dose granulocyte‐colony stimulating factor injections. Restorative Neurolology and 
Neuroscience. 2011;29(1):17–22
[39] Sharma A, Sane H, Kulkarni P, D’sa M, Gokulchandran N, Badhe P. Improved quality of 
life in a case of cerebral palsy after bone marrow mononuclear cell transplantation. Cell 
Journal. 2015;17(2):389–394
[40] Jensen A, Hamelmann E. First autologous cell therapy of cerebral palsy caused by 
hypoxic‐ischemic brain damage in a child after cardiac arrest‐individual treatment with 
cord blood. Case Report of Transplantation. 2013;2013:951827
[41] Wang L, Ji H, Zhou J, Xie J, Zhong Z, et al. Therapeutic potential of umbilical cord mes‐
enchymal stromal cells transplantation for cerebral palsy: A case report. Case Report of 
Transplantation. 2013;2013:146347.
[42] Luan Z, Qu SQ, Liu WP, et al. Treatment of heteroptics after cerebral palsy with trans‐
plantation of human neural stem cells into cerebral ventricle in infants: 7 case report. 
Zhongguo Kangfu Lilun yu Shijian. 2007;13(12):1103–1105
[43] Wang X, Cheng H, Hua R, Yang J, Dai G, Zhang Z, Wang R, Qin C, An Y. Effects of bone 
marrow mesenchymal stromal cells on gross motor function measure scores of children 
with cerebral palsy: A preliminary clinical study. Cytotherapy. 2013;15(12):1549–1562
Stem Cell Therapy in Pediatric Neurological Disabilities
http://dx.doi.org/10.5772/67656
137
[44] Wang X, Hu H, Hua R, Yang J, Zheng P, Niu X, Cheng H, Dai G, Liu X, Zhang Z, An Y. 
Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins 
with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors. 
Cytotherapy. 2015;17(2):224‐31.
[45] Zali A, Arab L, Ashrafi F, Mardpour S, Niknejhadi M, et al. Intrathecal injection of 
CD133‐positive enriched bone marrow progenitor cells in children with cerebral palsy: 
Feasibility and safety. Cytotherapy. 2015;17(2):232–241
[46] Mancías‐Guerra C, Marroquín‐Escamilla AR, González‐Llano O, Villarreal‐Martínez L, 
Jaime‐Pérez JC, et al. Safety and tolerability of intrathecal delivery of autologous bone 
marrow nucleated cells in children with cerebral palsy: An open‐label phase I trial. 
Cytotherapy. 2014;16(6):810–820
[47] Romanov YA, Tarakanov OP, Radaev SM, Dugina TN, Ryaskina SS, et al. Human allo‐
geneic AB0/Rh‐identical umbilical cord blood cells in the treatment of juvenile patients 
with cerebral palsy. Cytotherapy 2015;17(7):969–978
[48] Zhang C, Huang L, Gu J, Zhou X. Therapy for cerebral palsy by human umbilical cord 
blood mesenchymal stem cells transplantation combined with basic rehabilitation 
treatment: a case report. Global Pediatric Health. 2015;2:1–7
[49] Wang X, Hu H, Hua R, Yang J, Zheng P, et al. Effect of umbilical cord mesenchymal 
stromal cells on motor functions of identical twins with cerebral palsy: Pilot study on the 
correlation of efficacy and hereditary factors. Cytotherapy. 2015;17(2):224–231
[50] Shroff G, Gupta A, Barthakur JK. Therapeutic potential of human embryonic stem 
cell transplantation in patients with cerebral palsy. Journal of Translational Medicine. 
2014;12(1):1
[51] Abi Chahine NH, Wehbe TW, Hilal RA, Zoghbi VV, Melki AE, Bou Habib EB. Treatment 
of cerebral palsy with stem cells: A report of 17 cases. International Journal of Stem Cells. 
2016;9(1):90–95
[52] Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, et al. Consensus 
paper: Pathological role of the cerebellum in autism. Cerebellum (London, England) 
2012;11(3):777–807
[53] Sajdel‐Sulkowska EM, Xu M, McGinnis W, Koibuchi N. Brain region‐specific changes 
in oxidative stress and neurotrophin levels in autism spectrum disorders (ASD). 
Cerebellum. 2011;10(1):43–48
[54] Wada N, Gronthos S, Bartold PM. Immunomodulatory effects of stem cells. Periodontology 
2000. 2013;63(1):198–216
[55] Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, Werner C. 
Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 
2004;22(3):377–384
Physical Disabilities - Therapeutic Implications138
[56] Siniscalco D, Sapone A, Cirillo A,  Giordano C,  Maione S, Antonucci N, Autism Spectrum 
Disorders: Is Mesenchymal Stem Cell Personalized Therapy the Future? Journal of 
Biomedicine and Biotechnology, vol. 2012, Article ID 480289, 6 pages, 2012.
[57] Segal‐Gavish H, Karvat G, Barak N, Barzilay R, Ganz J, Edry L, Aharony I, Offen D, 
Kimchi T. Mesenchymal stem cell transplantation promotes neurogenesis and amelio‐
rates autism related behaviors in BTBR mice. Autism Research. 2016;9(1):17–32
[58] Sharma A, Gokulchandran N, Sane H, Nagrajan A, Paranjape A, et al. Autologous bone 
marrow mononuclear cell therapy for autism – An open label proof of concept study. 
Stem Cells International. 2013;2013:13 pages. Article ID 623875.
[59] Lv YT, Zhang Y, Liu M, Qiuwaxi J, Ashwood P, et al. Transplantation of human cord 
blood mononuclear cells and umbilical cord‐derived mesenchymal stem cells in autism. 
Journal of Translational Medicine. 2013;11:196
[60] Bradstreet JJ, Sych N, Antonucci N, Klunnik M, Ivankova O, Matyashchuk I, M Demchuk, 
Siniscalco D. Efficacy of fetal stem cell transplantation in autism spectrum disorders: An 
open‐labeled pilot study. Cell Transplantation, 2014;23:105–112
[61] Sharma A, Gokulchandran N, Badhe P, Kulkarni P, Mishra P, Shetty A, Sane H. An 
improved case of autism as revealed by PET CT scan in patient transplanted with 
autologous bone marrow derived mononuclear cells. Journal of Stem Cell Research and 
Therapy. 2013;3:2
[62] Sharma A, Gokulchandran N, Shetty A, Sane H, Kulkarni P, Badhe P. Autologous bone 
marrow mononuclear cells may be explored as a novel. Potential therapeutic option for 
autism. Journal of Clinical Case Reports. 2013;3:7
[63] Sharma A, Gokulchandran N, Sane H, Kulkarni P, Thomas N, Paranjape A, Badhe P. 
Intrathecal autologous bone marrow mononuclear cell transplantation in a case of adult 
autism. Autism Open Access. 2013;3:2
[64] Sharma A, Gokulchandran N, Sane H, Bhovad P, Biju H, Shetty A, Kali M, Badhe P. 
Cell therapy effects portrayed on positron emission tomography computerized tomog‐
raphy scan of the brain serve as a new dimension for autism: A case report. Journal of 
Paediatric Neurology. 2014;12:3
[65] Sharma A, Gokulchandran N, Shetty A, Kulkarni P, Sane H, Badhe P. Neuropsychiatric 
disorder tackled by innovative cell therapy – A case report in autism. Journal of Stem 
Cell Research Transplantation. 2014;1(1):4
[66] Sharma A, Gokulchandran N, Sane H, Patil A, Shetty A, Biju H, Kulkarni P, Badhe 
P. Amelioration of autism by autologous bone marrow mononuclear cells and 
neurorehabilitation: A case report. American Journal of Medical Case Reports. 
2015;3(10):304–309
Stem Cell Therapy in Pediatric Neurological Disabilities
http://dx.doi.org/10.5772/67656
139
[67] Sharma A, Sane H, Gokulchandran N, Badhe P, Patil A, Kulkarni P, Paranjape A. PET‐
CT scan shows decreased severity of autism after autologous cellular therapy: A case 
report. Autism Open Access. 2016;6:169
[68] Sharma A, Chopra G, Gokulchandran N, Lohia M, Kulkarni P. Autologous bone derived 
mononuclear transplantation in Rett syndrome. Journal of Paediatric Practice. 2011; 
15(1):22–24
[69] Kang H, Schuman EM. Long‐lasting neurotrophin‐induced enhancement of synaptic 
transmission in the adult hippocampus. Science. 1995;267:1658–1662
[70] Sharma A, Sane H, Paranjape A, Gokulchandran N, Kulkarni P, Nagrajan A, Badhe P. 
Positron emission tomography–computer tomography scan used as a monitoring tool 
following cellular therapy in cerebral palsy and mental retardation – A case report. Case 
Reports in Neurological Medicine. 2013;2013:6 pages. Article ID 141983
[71] Wallace GQ, McNally EM. Mechanisms of muscle degeneration, regeneration, and 
repair in the muscular dystrophies. Annual Review of Physiology. 2009;71:37–57
[72] Meregalli M, Farini A, Colleoni F, Cassinelli L, Torrente Y. The role of stem cells in mus‐
cular dystrophies. Current Gene Therapy. 2012;12(3):192–205
[73] Torrente Y, Belicchi M, Sampaolesi M, Pisati F, Meregalli M, D’Antona G, Tonlorenzi R, 
Porretti L, Gavina M, Mamchaoui K, Pellegrino MA. Human circulating AC133+ stem 
cells restore dystrophin expression and ameliorate function in dystrophic skeletal mus‐
cle. The Journal of Clinical Investigation. 2004;114(2):182–195.
[74] Goetzl L, Darbinian N, Goetzl EJ. Novel window on early human neurodevelopment 
via fetal exosomes in maternal blood. Annals of Clinical and Translational Neurology. 
2016;3(5):381–385
[75] Torrente Y, Belicchi M, Marchesi C, D’Antona G, Cogiamanian F, et al. Autologous 
transplantation of muscle‐derived CD133+ stem cells in Duchenne muscle patients. Cell 
Transplantation. 2007;16(6):563–577.
[76] Yang XF, Xu YF, Zhang YB, Wang HM, Lü NW, et al. Functional improvement of patients 
with progressive muscular dystrophy by bone marrow and umbilical cord blood mes‐
enchymal stem cell transplantations. Zhonghua Yi Xue Za Zhi. 2009;89(36):2552–2556
[77] Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk Z, Benson S, 
McAndrew PE, Rice R, Nagaraja H. Myoblast transfer in the treatment of Duchenne’s 
muscular dystrophy. New England Journal of Medicine. 1995;333(13):832–838
[78] Sharma A, Sane H, Badhe P, Gokulchandran N, Kulkarni P, Lohiya M, Biju H, Jacob VC. 
A clinical study shows safety and efficacy of autologous bone marrow mononuclear cell 
therapy to improve quality of life in muscular dystrophy patients. Cell Transplantation. 
2013;22(Suppl 1):S127‐S138
[79] Rajput BS, Chakrabarti SK, Dongare VS, Ramirez CM, Deb KD. Human umbilical cord 
mesenchymal stem cells in the treatment of Duchenne muscular dystrophy: Safety and 
feasibility study in India. Journal of Stem Cells. 2015;10(2):141
Physical Disabilities - Therapeutic Implications140
[80] Sharma A, Sane H, Gokulchandran N, Gandhi S, Bhovad P, Khopkar D, Paranjape A, 
Bhagwanani K, Badhe P. The role of cell transplantation in modifying the course of limb 
girdle muscular dystrophy: A longitudinal 5‐year study. Degenerative Neurological and 
Neuromuscular Disease. 2015;5:93–102
[81] Skuk D, Goulet M, Roy B, Piette V, Côté CH, Chapdelaine P, Hogrel JY, Paradis M, 
Bouchard JP, Sylvain M, Lachance JG. First test of a “high‐density injection” protocol 
for myogenic cell transplantation throughout large volumes of muscles in a Duchenne 
muscular dystrophy patient: eighteen months follow‐up. Neuromuscular Disorders. 
2007;17(1):38–46.
[82] Sharma A, Sane H, Paranjape A, Bhagawanani K, Gokulchandran N, Badhe P. Autologous 
bone marrow mononuclear cell transplantation in Duchenne muscular dystrophy – A 
case report. The American Journal of Case Reports. 2014;15:128.
[83] Sharma A, Paranjape A, Sane H, Bhagawanani K, Gokulchandran N, Badhe P. Cellular 
transplantation alters the disease progression in Becker’s muscular dystrophy. Case 
reports in transplantation. 2013;2013:7 pages. Article ID 909328
[84] Sharma A, Sane H, Paranjape A, Badhe P, Gokulchandran N, Jacob V. Effect of cellular 
therapy seen on musculoskeletal magnetic resonance imaging in a case of Becker’s mus‐
cular dystrophy. Journal of Case Reports. 2013;3(2):440–447
[85] Sharma A, Kulkarni P, Chopra G, Gokulchandran N, Lohia M, Badhe P. Autologous 
bone marrow‐derived mononuclear cell transplantation in Duchenne muscular dystro‐
phy. Indian Journal of Clinical Practice. 2012;23(3):169–172
[86] Sharma A, Sane H, Gokulchandra N, Sharan R, Paranjape A, Kulkarni P, Yadav J, Badhe 
P. Effect of cellular therapy in progression of Becker’s muscular dystrophy: A case study. 
European Journal of Translational Myology. 2016;26(1):5522
[87] Sharma A, Sane H, Kaur J, Gokulchandran N, Paranjape A, Yadav J, Badhe P. Autologous 
bone marrow mononuclear cell transplantation improves function in a case of Becker’s 
muscular dystrophy. American Based Research Journal. 2016;5(2):1–12
[88] Kang PB, Lidov HG, White AJ, Mitchell M, Balasubramanian A, et al. Inefficient dys‐
trophin expression after cord blood transplantation in Duchenne muscular dystrophy. 
Muscle & Nerve. 2010;41(6):746–750
[89] Skuk D, Roy B, Goulet M, Chapdelaine P, Bouchard JP, Roy R, Dugré FJ, Lachance JG, 
Deschênes L, Senay H, Sylvain M. Dystrophin expression in myofibers of Duchenne 
muscular dystrophy patients following intramuscular injections of normal myogenic 
cells. Molecular Therapy. 2004;9(3):475–482
[90] Zhang C, Chen W, Xiao LL, Tan EX, Luo SK, Zheng D, Ye X, Li Z, Lu XL, Liu Y. 
Allogeneic umbilical cord blood stem cell transplantation in Duchenne muscular dys‐
trophy. Zhonghua Yi Xue Za Zhi. 2005;85(8):522–525
[91] Hentze H, Graichen R, Colman A. Cell therapy and the safety of embryonic stem cell‐
derived grafts. Trends in Biotechnology. 2007;25(1):24–32
Stem Cell Therapy in Pediatric Neurological Disabilities
http://dx.doi.org/10.5772/67656
141
[92] Montoro J, Piñana JL, Moscardó F, Sanz J. Infectious complications after umbilical cord‐
blood transplantation from unrelated donors. Mediterranean Journal of Hematology 
and Infectious Diseases. 2016;8(1):e2016051
[93] Sharma A, Sane H, Paranjape A, Gokulchandran N, Takle M, et al. Seizures as an 
adverse event of cellular therapy in pediatric neurological disorders and its prevention. 
Journal of Neurological Disorders. 2014;2:164
[94] Minguell JJ, Pereira A, Bartholomew P, Lasala GP. The intrathecal infusion of mes‐
enchymal stem cells into healthy rabbits is safe and devoid of neurological or clinical 
complications. Journal of Stem Cell Research and Therapy. 2011;1:104
[95] Xu Q, Zhang M, Liu J, Li W. Intrathecal transplantation of neural stem cells appears 
to alleviate neuropathic pain in rats through release of GDNF. Annals of Clinical and 
Laboratory Science. 2013;43(2):154–162
[96] Torrente. Y, Belicchi M, Marchesi C, D’Antona G. Autologous transplantation of mus‐
cle‐derived CD133+ stem cells in Duchenne muscle patients. Cell Transplantation. 
2007;16(6):563–577
[97] Fischer UM, Harting MT, Jimenez F, Monzon‐Posadas WO, Xue H, Savitz SI, Laine GA, 
Cox CS Jr. Pulmonary passage is a major obstacle for intravenous stem cell delivery: 
The pulmonary first‐pass effect. Stem Cells and Development. 2009;18(5):683–692
[98] Boltze J, Arnold A, Walczak P, Jolkkonen J, Cui L, Wagner DC. The dark side of the force – 
constraints and complications of cell therapies for stroke. Frontiers of Neurology. 2015; 
6:155
[99] Wang X, Zhang M, Feng R, Li WB, Ren SQ, Zhang J, Zhang F. Physical exercise training 
and neurovascular unit in ischemic stroke. Neuroscience. 2014;271:99–107
[100] Wahl P, Brixius K, Bloch W. Exercise‐induced stem cell activation and its implication 
for cardiovascular and skeletal muscle regeneration. Minimally Invasive Therapy & 
Allied Technologies. 2008;17(2):91–99
[101] Acton PD, Zhou R. Imaging reporter genes for cell tracking with PET and SPECT. 
Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2005;49(4):349–360
[102] Berti V, Mosconi L, Pupi A. Brain: Normal variations and benign findings in FDG PET/
CT imaging. PET Clinics. 2014;9(2):129–140
[103] Mercuri E, Jungbluth H, Muntoni F. Muscle imaging in clinical practice: diagnostic 
value of muscle magnetic resonance imaging in inherited neuromuscular disorders. 
Current Opinion of Neurology. 2005;18:526–537
[104] Klotzenburg M, Yousry T. Magnetic resonance imaging of skeletal muscle. Current 
Opinion of Neurology. 2007;20:595–599
Physical Disabilities - Therapeutic Implications142
